Mounjaro may weaken the pill, Sweden’s medicines agency warns

Women taking Mounjaro alongside the contraceptive pill are being advised to add a barrier method for four weeks after starting treatment and after every dose increase, or switch to contraception that is not taken by mouth.
Sweden’s Medical Products Agency issued the advice on 19 November after European medicines experts adopted new recommendations over the possibility that tirzepatide, Mounjaro’s active ingredient, could reduce the pill’s effectiveness.
The agency says information remains limited on how tirzepatide affects oral contraceptives in women with obesity, overweight or type 2 diabetes. Women who could become pregnant were already advised to use contraception while taking the medicine.
Mounjaro is used alongside diet and physical activity to treat insufficiently controlled type 2 diabetes. It is also authorised for weight management in adults with obesity, or overweight accompanied by weight-related health problems.
A letter to healthcare professionals will set out the new recommendations. The four-week barrier precaution applies both when treatment begins and whenever the dose rises.
